CapWealth Advisors LLC Purchases 1,712 Shares of Stryker Corporation (NYSE:SYK)

CapWealth Advisors LLC lifted its stake in Stryker Corporation (NYSE:SYK - Free Report) by 5.9% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 30,938 shares of the medical technology company's stock after buying an additional 1,712 shares during the period. CapWealth Advisors LLC's holdings in Stryker were worth $11,517,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Capital A Wealth Management LLC bought a new stake in shares of Stryker in the fourth quarter valued at approximately $26,000. Rakuten Securities Inc. boosted its stake in shares of Stryker by 618.2% in the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock valued at $28,000 after buying an additional 68 shares during the period. Goodman Advisory Group LLC bought a new stake in shares of Stryker in the first quarter valued at approximately $32,000. City Holding Co. raised its position in Stryker by 528.6% during the first quarter. City Holding Co. now owns 88 shares of the medical technology company's stock valued at $33,000 after purchasing an additional 74 shares in the last quarter. Finally, VSM Wealth Advisory LLC acquired a new position in Stryker during the fourth quarter valued at approximately $36,000. 77.09% of the stock is currently owned by institutional investors.

Stryker Trading Down 0.7%

Shares of Stryker stock traded down $2.86 during trading on Tuesday, hitting $389.65. The company's stock had a trading volume of 1,195,342 shares, compared to its average volume of 1,347,476. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.64 and a quick ratio of 1.00. Stryker Corporation has a 52 week low of $314.93 and a 52 week high of $406.19. The stock has a market cap of $148.73 billion, a price-to-earnings ratio of 52.66, a price-to-earnings-growth ratio of 2.98 and a beta of 0.91. The stock has a 50-day moving average price of $383.44 and a two-hundred day moving average price of $376.58.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.84 earnings per share for the quarter, topping the consensus estimate of $2.73 by $0.11. Stryker had a net margin of 12.31% and a return on equity of 23.74%. The company had revenue of $5.87 billion for the quarter, compared to analysts' expectations of $5.68 billion. During the same quarter in the previous year, the firm posted $2.50 earnings per share. Stryker's revenue for the quarter was up 11.9% on a year-over-year basis. Equities research analysts anticipate that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Monday, June 30th will be given a dividend of $0.84 per share. The ex-dividend date is Monday, June 30th. This represents a $3.36 dividend on an annualized basis and a yield of 0.86%. Stryker's dividend payout ratio (DPR) is currently 45.41%.

Wall Street Analysts Forecast Growth

Several brokerages have commented on SYK. JMP Securities restated a "market perform" rating on shares of Stryker in a research report on Monday, May 5th. Needham & Company LLC restated a "buy" rating and set a $442.00 price objective on shares of Stryker in a research report on Friday, March 21st. Evercore ISI boosted their price objective on shares of Stryker from $390.00 to $415.00 and gave the company an "outperform" rating in a research report on Tuesday. Truist Financial boosted their price objective on shares of Stryker from $390.00 to $400.00 and gave the company a "hold" rating in a research report on Monday, May 5th. Finally, Sanford C. Bernstein set a $450.00 price objective on shares of Stryker in a research report on Monday, May 5th. Five investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $428.55.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the company's stock in a transaction on Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the sale, the director owned 3,417,326 shares of the company's stock, valued at approximately $1,288,195,208.96. This represents a 5.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 5.20% of the company's stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.